Cost-Effectiveness Analysis of Atezolizumab plus Pemetrexed and Platinum in First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer in China
- 1 China Pharmaceutical University, Nanjing, China
- 2 School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China
Abstract
Objective: To evaluate the cost-effectiveness of atezolizumab plus pemetrexed and platinum-based (APP) in the first-line treatment of non-squamous non- small cell lung cancer (NSCLC). Methods: A partitioned survival model (PSM) was constructed based on the IMpower132 clinical trial. Total cost, quality- adjusted life years (QALY), and incremental cost-effectiveness ratio (ICER) were the main outputs of the model. Deterministic sensitivity analysis and probabilistic sensitivity analysis were adopted to test the uncertainty of the parameters. Results: The results of the base-case analysis illustrated that compared with PP, the incremental cost of APP was CNY 591040.94, the incremental utility was 0.46 QALY, and the ICER was CNY 1291414.83/QALY. Deterministic sensitivity analysis results illustrated that atezolizumab and other parameters have a greater impact on ICER. Probabilistic sensitivity analysis results show that no matter how each parameter changes, under the willingness to pay threshold of 3-times Chinese per capita GDP, the probability of APP has cost-effectiveness is 0. Conclusion: From the perspective of the Chinese health system, APP is not cost-effective for first-line treatment of non-squamous non-small cell lung cancer without sensitizing EGFR or ALK genetic alterations.
- Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Abate, D., et al. (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study The Journal of the American Medical Association Oncology, 5, 1749-1768. https://doi.org/10.1001/jamaoncol.2019.2996
- American Cancer Society (2019) What Is Non-Small Cell Lung Cancer? https://www.cancer.org/cancer/lung-cancer/about/what-is.html
- Paz-Ares, L., Ciuleanu, T.E., Cobo, M., et al. (2021) First-Line Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211. https://doi.org/10.1016/S1470-2045(20)30641-0
- Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., et al. (2020) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517. https://doi.org/10.1200/JCO.19.03136
- Nishio, M., Barlesi, F., West, H., et al. (2021) Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. Journal of Thoracic Oncology, 16, 653-664. https://doi.org/10.1016/j.jtho.2020.11.025
- Woods, B.S., Sideris, E., Palmer, S., Latimer, N. and Soares, M. (2020) Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? Value Health, 23, 1613-1621. https://doi.org/10.1016/j.jval.2020.08.2094
- Schwartz, L.H., Litière, S., de Vries, E., et al. (2016) RECIST 1.1—Update and Clarification: From the RECIST Committee. European Journal of Cancer, 62, 132-137. https://doi.org/10.1016/j.ejca.2016.03.081
- Insinga, R.P., Vanness, D.J., Feliciano, J.L., Vandormael, K., Traore, S. and Burke, T. (2018) Cost-Effectiveness of Pembrolizumab in Combination with Chemotherapy in the 1st Line Treatment of Non-Squamous NSCLC in the US. Journal of Medical Economics, 21, 1191-1205. https://doi.org/10.1080/13696998.2018.1521416
- Liu, G.E., Hu, S.L., Wu, J.H., et al. (2020) China Guidelines for Pharmacoeconomic Evaluations 2020 (Chinese-English Version). China Market Press, Beijing.
- Guyot, P., Ades, A.E., Ouwens, M.J. and Welton, N.J. (2012) Enhanced Secondary Analysis of Survival Data: Reconstructing the Data from Published Kaplan-Meier Survival Curves. BioMed Central Medical Research Methodology, 12, Article No. 9. https://doi.org/10.1186/1471-2288-12-9